No Data
Express News | Inventisbio Announces Positive Phase 2 Study Results for D-2570 (Tyk2 Inhibitor) in Patients With Moderate to Severe Plaque Psoriasis
InventisBio Announces Positive Phase 2 Study Results for D-2570 (TYK2 Inhibitor) in Patients With Moderate to Severe Plaque Psoriasis
Yifang Biotechnology (688382.SH): D-2570 Phase II clinical trial achieved positive clinical trial results.
On December 3, Glonghui reported that Yifang Bio (688382.SH) announced that its self-developed targeted TYK2 novel oral selective inhibitor D-2570 has recently completed a Phase II clinical trial for psoriasis, achieving positive clinical trial results. This trial is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical study aimed at assessing the efficacy and safety of D-2570 in treating moderate to severe plaque psoriasis. According to the trial protocol, a total of 161 psoriasis patients were recruited for the trial, divided into groups to take three different doses of D-2570 and a placebo. The main results of the trial are...
InventisBio Co., Limited's (SHSE:688382) Market Cap Dropped CN¥1.1b Last Week; Retail Investors Bore the Brunt
InventisBio Gets Regulatory Approval to Market Gesorexel Tablets
Yifang Bio (688382.SH): Class 1 innovative drug Goserelin acetate tablets approved for listing.
Yifang Biology (688382.SH) announced that the company has entered into an agreement with Zhengda Tianqing Pharmaceutical Group Co., Ltd. (referred to as "...
